The Clinical Dilemma of Vanishing Lesions after Systemic Therapy in Oligometastatic Esophagogastric Cancer: A Narrative Review
Digestive Surgery · 14.07.2026 · 1-7
DOI: 10.1159/000553588 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive Surgery, online erschienen am 14.07.2026. Verfasst von Sebastiaan F C Bronzwaer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Amsterdam UMC (Vrije Universiteit), Amsterdam, The Netherlands, s.f.c.bronzwaer@umcutrecht.nl. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background: Radical local metastasis-directed treatment is increasingly considered in oligometastatic cancer. Disappearance of metastases after systemic therapy (“vanishing lesions”) poses management dilemmas, as invisibility does not prove complete response, but local therapy carries morbidity. Summary: We searched PubMed for studies on vanishing metastases after systemic therapy in esophagogastric cancer. Complete disappearance of all metastases occurred in 1–3% of patients treated with chemotherapy alone and in 5–17% in trials using targeted or immune therapies. Series reported ≥1 vanishing lesion(s) in 8–44% of patients. Definitions relied on CT, without comparison to MRI or PET-CT. Lesion-level pathology was lacking; vanishing sites were not resected. Survival benefits were linked to radiologic complete response, but the impact of locally treating vanishing sites was not studied. Because esophagogastric data are scarce, colorectal metastases were reviewed for context: CT disappearance often overestimated cure, liver MRI frequently altered plans, 33–69% of CT/MRI-negative liver lesions still harbored viability or recurred, and survival was comparable between unresected vs. resected vanishing lesions. Key Messages: Current evidence does not support routine local treatment of vanishing lesions in oligometastatic esophagogastric cancer, although this conclusion is based on a very limited and retrospective evidence base. Imaging besides CT (e.g., MRI, PET-CT) may improve staging. Individualized benefit-risk assessment and studies addressing diagnostic and therapeutic strategies are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Amsterdam UMC (Vrije Universiteit), Amsterdam, The Netherlands, s.f.c.bronzwaer@umcutrecht.nl.
- Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands, s.f.c.bronzwaer@umcutrecht.nl.
- Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Department of Oncology, Amsterdam UMC (University of Amsterdam), Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.
Zitieren
APA
Bronzwaer, S. F. C., Haarlem, I. V., Kroese, T. E., van Laarhoven, H. W. M., Ruurda, J. P., van Hillegersberg, R., & van Rossum, P. S. N. (2026). The Clinical Dilemma of Vanishing Lesions after Systemic Therapy in Oligometastatic Esophagogastric Cancer: A Narrative Review. Digestive Surgery, 1-7. https://doi.org/10.1159/000553588
Vancouver
Bronzwaer SFC, Haarlem IV, Kroese TE, van Laarhoven HWM, Ruurda JP, van Hillegersberg R, et al. The Clinical Dilemma of Vanishing Lesions after Systemic Therapy in Oligometastatic Esophagogastric Cancer: A Narrative Review. Digestive Surgery. 2026:1-7. doi:10.1159/000553588
BibTeX
@article{Bronzwaer2026,
author = {Bronzwaer, Sebastiaan F C and Haarlem, Iris van and Kroese, Tiuri E and van Laarhoven, Hanneke W M and Ruurda, Jelle P and van Hillegersberg, Richard and van Rossum, Peter S N},
title = {The Clinical Dilemma of Vanishing Lesions after Systemic Therapy in Oligometastatic Esophagogastric Cancer: A Narrative Review},
journal = {Digestive Surgery},
year = {2026},
pages = {1--7},
doi = {10.1159/000553588}
}
EUVIMED